Evaluation of the safety and efficacy of a monoclonal antibody to treat Influenza

Study identifier:D6000C00004

ClinicalTrials.gov identifier:NCT03903718

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase 1/2a Clinical Study to Evaluate the Efficacy of MEDI8852 in the Treatment of Influenza in Adults Challenged with a Wild-Type Influenza Strain

Medical condition

Influenza

Phase

Phase 2

Healthy volunteers

Yes

Study drug

Oseltamivir, Placebo

Sex

All

Actual Enrollment

0

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 03 Apr 2020
Estimated Primary Completion Date: 09 Oct 2020
Estimated Study Completion Date: 09 Oct 2020

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2020 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria